Innate Pharma Sa (IPHA) Stock News

Innate Pharma (NASDAQ:IPHA) has released its updated share capital and voting rights information as of August 1, 2025. The company reported 92,184,823 ordinary shares outstanding, along with 6,424 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The company's total theoretical voting rights stand at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements and AMF recommendations.

Innate Pharma (NASDAQ:IPHA) announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025. The company's CEO Jonathan Dickinson and COO Yannis Morel will represent Innate at the event.

The company will participate in a Fireside chat on Wednesday July 30 at 2:00 PM EST, followed by one-on-one meetings. Notably, BTIG, which recently initiated analyst coverage of Innate Pharma, is hosting this conference as part of their global financial services offerings.

Innate Pharma (NASDAQ:IPHA) has disclosed its updated share capital and voting rights structure as of July 3, 2025. The company reported 92,183,523 ordinary shares outstanding, along with 6,434 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements and AMF recommendations.

Innate Pharma (Nasdaq: IPHA) has announced its upcoming participation in two major healthcare investor conferences in June 2025. The company's executive team will attend the H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference on June 24, 2025, and the Wolfe Research Virtual Biotech Day on June 26, 2025. Both events will be held virtually, providing opportunities for Innate Pharma to engage with investors and showcase their developments in the biotechnology sector.

Innate Pharma (IPHA) presented preclinical data for IPH6501, their proprietary ANKET® targeting CD20, at the 2025 EHA Congress. The drug demonstrated potent antitumor activity in DLBCL and FL patient samples. In preclinical studies, IPH6501 showed strong efficacy in rituximab-resistant models and enhanced antitumor activity when combined with R-CHOP standard therapy, leading to sustained tumor eradication. The drug is currently in Phase 1/2 clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma. The results suggest IPH6501's potential to improve treatment outcomes for both treatment-naive and R/R B-NHL patients, addressing significant unmet medical needs in DLBCL and FL treatment.

Innate Pharma (NASDAQ: IPHA) has announced its participation in multiple upcoming healthcare conferences in June 2025. The company's executive team will present at the Jefferies Global Healthcare Conference in New York (June 3-5), with a fireside chat scheduled for June 5 at 7:35 am EDT. They will also participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami (June 9-11), with a fireside chat set for June 10 at 4:00 pm EDT.

Additionally, the executive team will attend the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025.

Innate Pharma (IPHA) held its Annual General Meeting on May 22, 2025, where shareholders approved all resolutions with a quorum of 47.14%. The key highlight was the company's transition from an Executive Board and Supervisory Board structure to a Board of Directors structure with a Chief Executive Officer.

The newly formed Board includes eight members, with Mrs. Irina Staatz-Granzer appointed as Chairman of the Board and Mr. Jonathan Dickinson as Chief Executive Officer, marking a separation of these two key roles. This governance change aims to align the company with international standards.

Innate Pharma (IPHA) has announced compelling long-term follow-up data from the Phase 2 TELLOMAK trial evaluating lacutamab in treating Sézary syndrome (SS) and mycosis fungoides (MF). The trial demonstrated significant results with a 42.9% overall response rate in SS patients and an impressive median duration of response of 25.6 months. For MF patients, the study showed a 19.6% overall response rate with a median duration of response of 13.8 months. Notably, lacutamab was recently granted Breakthrough Therapy Designation by the FDA for Sézary syndrome treatment. The drug showed strong tolerability and effectiveness in heavily pretreated patients, with anti-tumor activity observed across all patients regardless of KIR3DL2 expression levels. The company is now preparing for a Phase 3 trial to advance this promising therapy.

Innate Pharma (NASDAQ: IPHA) announced the selection of four abstracts featuring its clinical development drugs for presentation at the ASCO 2025 Annual Meeting (May 30-June 3, 2025). The presentations include long-term follow-up data from the TELLOMAK Phase 2 trial studying lacutamab in Sézary syndrome and mycosis fungoides patients, a trial in progress poster for IPH4502 in advanced solid tumors expressing Nectin-4, and AstraZeneca's poster on updated results from the NeoCOAST-2 Phase 2 trial of monalizumab in resectable non-small-cell lung cancer (NSCLC).